Abstract
Bispecific antibodies that bind to a tumor antigen and the T cell receptor (TCR) redirect cytotoxic T lymphocytes (CTL) to lyse tumor cells which have escaped normal immune recognition mechanisms. One well-characterized tumor antigen, the folate receptor (FR), is expressed on most ovarian carcinomas and some types of brain cancer. Recently, it was shown that conjugates of folate and anti-TCR antibodies are extremely potent bispecific agents that target tumor cells expressing the high-affinity folate receptor, but not normal cells expressing only the reduced folate carrier protein. In this paper, it is shown that the size of these conjugates can be reduced to the smallest bispecific agent yet described (30 kDa) by attaching folate to a single-chain antibody, scFv, of the anti-TCR antibody KJ16. The scFv/folate conjugates are as effective as IgG/folate conjugates in mediating lysis of FR4 tumor cells by CTL. The optimal folate density was in the range of 5-15 folate molecules per scFv or IgG molecule, which yielded half-maximal lysis values (EC50) of approximately 40 pM (1.2 ng/mL for scFv). Finally, the scFv/folate conjugates could efficiently target tumor cells even in the presence of free folic acid at concentrations that are ...Continue Reading
References
Sep 1, 1976·Journal of Neurosurgery·G J DohrmannJ T Flannery
Jun 1, 1992·Japanese Journal of Cancer Research : Gann·Y SugiyamaO Alper
Jan 1, 1992·Journal of Neuro-oncology·J AllenE Arenson
Aug 1, 1984·The Journal of Experimental Medicine·K HaskinsP Marrack
Jul 1, 1995·Journal of Clinical Pathology·M R BuistC J Meijer
Oct 4, 1995·Journal of the National Cancer Institute·S CanevariC H Lamers
Feb 8, 1995·International Journal of Cancer. Journal International Du Cancer·C H LamersR L Bolhuis
Jan 1, 1994·Journal of Neuro-oncology·S D WeitmanB A Kamen
Jan 1, 1994·Annual Review of Immunology·G WinterH R Hoogenboom
Jan 1, 1994·Journal of Drug Targeting·C P Leamon, P S Low
Aug 19, 1993·International Journal of Cancer. Journal International Du Cancer·H H van Ravenswaay ClaasenG J Fleuren
Oct 1, 1995·Journal of Hematotherapy·J ChenE D Ball
Citations
Jun 5, 2008·Cancer Metastasis Reviews·Emanuela I Sega, Philip S Low
Apr 20, 2004·Advanced Drug Delivery Reviews·Christopher P Leamon, Joseph A Reddy
Apr 20, 2004·Advanced Drug Delivery Reviews·Yingjuan LuPhilip S Low
Aug 23, 2001·Journal of Immunological Methods·A GuptaV K Chaudhary
Oct 8, 1999·Pharmacology & Therapeutics·G M Dubowchik, M A Walker
Aug 23, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yingjuan Lu, Philip S Low
Sep 19, 1998·Journal of Controlled Release : Official Journal of the Controlled Release Society·D M KranzE J Roy
Sep 1, 2000·Advanced Drug Delivery Reviews·S P Vyas, V Sihorkar
Feb 13, 2001·Drug Discovery Today·C P. Leamon, P S. Low
Jul 30, 1999·Journal of Controlled Release : Official Journal of the Controlled Release Society·K E AndersonJ A Rogers
Mar 24, 2011·Journal of Drug Targeting·Gauri MishraAnil K Mishra
Sep 2, 2005·Journal of Pharmaceutical Sciences·Andrew R Hilgenbrink, Philip S Low
Dec 29, 2007·International Journal of Pharmaceutics·Abhinav AgarwalNarendra K Jain
Apr 20, 2004·Advanced Drug Delivery Reviews·Edward J RoyDavid M Kranz
Jul 28, 2016·Organic & Biomolecular Chemistry·Smita B Gunnoo, Annemieke Madder
Jun 4, 1998·International Journal of Cancer. Journal International Du Cancer·E J RoyD M Kranz
Aug 13, 2011·Organic & Biomolecular Chemistry·Grazia M L ConsoliCorrada Geraci
Aug 17, 1999·International Journal of Cancer. Journal International Du Cancer·L A RundD M Kranz
Nov 18, 2020·BMC Cancer·Cari A Didion, Walter A Henne
Jun 17, 2005·Cancer Research·Jolanta F Kukowska-LatalloJames R Baker
Oct 2, 2004·Journal of Inorganic Biochemistry·Gregory Russell-JonesDavid Nowotnik
Jul 30, 2010·Journal of Medicinal Chemistry·Wei Xia, Philip S Low
Aug 19, 2008·International Journal of Biological Macromolecules·Ajun WanHuili Li